Amneal Pharmaceuticals Inc. (AMRX) — RQD Stock Rating Cockpit
Amneal Pharmaceuticals Inc. (AMRX) receives a Roarable Rating of D+ (Sell) and flashes a Red SELL / AVOID warning (65/100 RQD Confidence). Our SEC filing scanner spotted paper earnings outpacing real operating cash flow (+146.4% (NI vs OCF)) while unpaid customer invoices grew—a classic sign to step aside until cash flow catches up.
Warning: Paper profits outpaced real cash collected while unpaid invoices rose—classic earnings quality red flag.
Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.
Our SEC fine-print scanner flagged elevated accounting or executive-hedging risk combined with interest-rate headwinds.
JEV AI Jury Split (Battleground) on AMRX
14.1% ROIC with 36.9% gross margin and 3.63% FCF yield.
Flagged cash-conversion divergence or elevated filing risk disclosures.
Put/Call 0.75x with 22/40 institutional & insider flow.
- ✓Established market leader in Health Care with deep daily trading liquidity.
- !Headline earnings grew much faster than real operating cash flow—watch out for profit revisions.
- !Priced at 103x earnings—high expectations leave less room for a lukewarm quarter.
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring AMRX)
- ✓Live walkthrough of AMRX's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
AMRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +8.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on AMRX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for AMRX. Explore sector supply chains on /butterfly.
AMRX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDShould I buy, hold, or sell AMRX stock right now?
Amneal Pharmaceuticals Inc. (AMRX) currently earns a Roarable Rating of D+ (Sell — SELL) with 65/100 RQD Confidence. Accounting Warning: Paper earnings outpaced operating cash flow (+146.4% (NI vs OCF)) as receivables rose.
What is AMRX's 12-month price target and RQD AI Jury consensus?
AMRX's 12-month base price target is $22.02 (range $17.18 to $25.98), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.